Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Phase I Trial of Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed/ Refractory Non-Hodgkin Lymphoma
Sponsor: Paolo Caimi, MD
This PHASE1 trial investigates Refractory Non-Hodgkin Lymphoma and Relapsed Non Hodgkin Lymphoma and is currently ongoing. Paolo Caimi, MD leads this study, which shows 13 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jun 2022 — Aug 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Paolo Caimi, MD
For direct contact, visit the study record on ClinicalTrials.gov .